A Case Report for Severe COVID-19 in a 9-Year-Old Child Treated with Remdesivir and Dexamethasone

Yoon Hee Jo, Yosub Hwang, and Soo-Han Choi

Department of Pediatrics, Pusan National University Hospital, Busan, Korea

ABSTRACT

Coronavirus disease 2019 (COVID-19) is generally milder in children than in adults, and a substantial proportion of children with the disease have asymptomatic infections. Remdesivir is recommended for severe COVID-19. To date, there are little data on the outcomes of remdesivir treatment in children. We report a case of severe COVID-19 in a previously healthy but obese (body mass index, 27.6; 99.8th percentile of the age) 9-year-old boy treated with remdesivir and dexamethasone. The patient had pneumonia at the time of diagnosis and required supplemental oxygen due to hypoxia one day after diagnosis. The patient developed respiratory distress as his pneumonia progressed rapidly. Therefore, remdesivir with dexamethasone therapy was initiated on hospital day 2. Supplemental oxygen was gradually weaned on hospital day 6 and stopped on hospital day 9. Significant improvement in pneumonic consolidations on chest X-ray was noted on hospital day 8. The patient was discharged on hospital day 21. We did not observe any adverse effects of remdesivir therapy and successfully treated a 9-year-old child with severe COVID-19.

Keywords: COVID-19; Child; Remdesivir

INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic has affected more than 161 million worldwide, and caused more than three million deaths.1 Children and adolescents are generally at low risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and if they become infected, the disease is likely to be mild.2-5 However, some children and adolescents have had severe experiences with COVID-19, and a few have died.3,6-10 As of May 6, 2021, over 3.85 million children have tested positive for COVID-19 in the United States, representing 14% of all cases. In state-level reports, children accounted for 0.00–0.21% of all COVID-19 deaths.3 In South Korea during the same period, 14,341 children 0 to 19 years of age were confirmed with COVID-19.11 However, no COVID-19-related mortality among Korean children have been reported so far.11

Remdesivir is an antiviral drug with potent in vitro activity against a range of RNA viruses including SARS-CoV-2.12 Remdesivir is recommended for patients with severe COVID-19 but
is not necessary for most pediatric COVID-19 patients. Here, we reported on a 9-year-old boy with COVID-19 pneumonia who developed respiratory distress and was successfully treated with remdesivir and dexamethasone.

CASE DESCRIPTION

On May 4, 2021, a 9-year-old boy confirmed with COVID-19 was referred to our hospital. Fig. 1 shows the timeline before hospitalization to our hospital. Because his uncle, whom he had contact with at a family reunion, was confirmed with asymptomatic COVID-19, he had been in self-quarantine since 10 days earlier. He had a cough on the seventh day of self-quarantine (nine days after the last exposure) and developed a fever of ≥ 38°C the next evening. He was eventually confirmed with COVID-19 12 days after the last exposure and was hospitalized in a designated hospital. Upon admission to the outside hospital, the initial chest X-ray showed diffuse pneumonic consolidations in both lung fields and chest computer tomography was performed on the same day (Fig. 2). He had a fever of up to 40.5°C, cough, and sputum, but no dyspnea, and his saturation of percutaneous oxygen (SpO₂) was maintained at ≥ 95% on room air. However, the next day, his fever and cough became worse, and he complained of respiratory difficulty.

The patient was previously healthy and had no specific medical history other than obesity (body mass index, 27.6, 99.8th percentile; body weight, 62 kg, 99.8th percentile; height, 150 cm, 97.3rd percentile). The initial vital signs at our hospital showed a blood pressure of 124/106 mmHg, pulse rate of 133 beats per minute, respiratory rate of 29 breaths per minute, a body temperature of 38.6°C, and an SpO₂ of 95–98% on room air. The initial laboratory results were as follows: white blood cell count 6,760/μL (13.9% lymphocytes), hemoglobin 11.7 g/dL, platelet count 238,000/μL, C-reactive protein 8.29 mg/dL (range, 0–0.5), procalcitonin 0.86 ng/mL (range, 0-0.05), and D-dimer 0.7 μg/mL (range, 0-0.5). The cardiac biomarkers were normal. The results of arterial blood gas analysis were pH 7.48, pCO₂ 31 mmHg, pO₂ 103 mmHg, and O₂ saturation 98%. However, he gradually complained of respiratory difficulty starting on the night of hospitalization day and had oxygen desaturation. Oxygen supplementation was needed to maintain an SpO₂ of ≥ 95%. He received supplemental oxygen via nasal prongs initially. The clinical course and selected relevant laboratory parameters are shown in Fig. 3.

On hospital day 2, he developed markedly increased tachypnea (respiratory rate up to 48 breaths per minute) and decreasing SpO₂, thus requiring oxygen enrichment (up to 5 L flow of 100% oxygen). The chest X-ray showed the progression of pneumonia (Fig. 4). We assessed the patient’s COVID-19 severity based on clinical criteria, which was regarded as severe. Remdesivir is suggested for children with severe COVID-19, so remdesivir administration...
was initiated (body weight ≥ 40 kg: 200 mg loading dose on the first day, followed by 100 mg every 24 hours intravenously). Although hypotension was not noted, other vital signs remained unstable. He had sustained and recurrent fever with poor response to antipyretics, tachycardia, tachypnea, and repeated need for increase in oxygen. He complained of severe general aches, and the C-reactive protein level was high. We decided to administer corticosteroids. He received dexamethasone at 6 mg (0.15 mg/kg, maximum dose 6 mg) once daily for 10 days.

The patient showed defervescence by hospital day 4. However, he complained of severe cough and had frequent desaturation of SpO2. In the episodes of deterioration, his oxygen requirement increased up to 10 L/min and slowly recovered. There were no significant findings in testing for additional bacterial and viral respiratory pathogens. The echocardiography results were unremarkable. The five days of remdesivir therapy were finished on hospital day 6. Hepatic and renal function tests were monitored daily during...
Remdesivir Therapy in a Child with COVID-19

| Hospital Day | #1  | #2  | #3  | #4  | #5  | #6  | #7  | #8  | #9  | #10 | #11 |
|--------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Fever (≥ 38°C) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) |
| Oxygen therapy | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) |
| Remdesivir | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) |
| Dexamethasone | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) |
| Antibiotics | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) | ![Timeline](https://jkms.org) |
| White cell count (µL) | 6,760 | 5,190 | 2,980 | 5,650 | 7,260 | 10,960 | 12,380 |
| Absolute lymphocyte count (µL) | 939 | 711 | 831 | 1,248 |
| C-reactive protein (mg/L) | 8.29 | 14.8 | 2.91 | 0.45 | 0.16 |
| SARS-CoV-2 PCR E gene, ORF1ab gene Ct (cycle threshold) value | Positive E 26.83 ORF1ab 25.24 | Positive E 33.19 ORF1ab 30.47 |

Fig. 3. Timeline of clinical course, treatment and laboratory findings. SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, PCR = polymerase chain reaction.

**Fig. 4.** Serial chest X-rays of the patient. The patient received remdesivir therapy from HD 2 to 6. HD = hospital day.
remdesivir therapy, and there were no adverse events. Although there was no significant improvement in the chest X-ray on hospital day 6, his oxygen requirements were gradually weaning. On hospital day 8, the chest X-ray showed a marked improvement in pneumonic consolidations in both lung fields (Fig. 4), and the C-reactive protein level was normal. Supplemental oxygen was stopped on hospital day 9.

The follow-up polymerase chain reaction (PCR) test for SARS-CoV-2 on hospital day 18 was equivocal (negative for E gene; positive for ORF 1ab; cycle threshold value, 35.11). However, no pneumonic consolidations were noted on the follow-up chest X-ray, and his symptoms had nearly resolved. The patient was discharged from the hospital on day 21.

**Ethics statement**

This study was approved by the Institutional Review Board (IRB) of Pusan National University Hospital and the requirement for informed consent was waived (IRB No. 2105-024-103).

**DISCUSSION**

We report a case of severe COVID-19 in a previously healthy 9-year-old boy in Korea. This child developed respiratory distress as his pneumonia progressed rapidly. He received remdesivir treatment and recovered successfully.

There is no international consensus on the classification of the disease severity of pediatric COVID-19. In the early phase of the COVID-19 pandemic, radiological criteria were considered an essential factor in the classification of disease severity. However, radiographic infiltrates are common, even among well-appearing, clinically stable children with COVID-19. Therefore, a severity classification that includes a radiological diagnosis of pneumonia is not appropriate for children. Several recent reports have used clinical criteria, particularly respiratory support requirements, to define illness severity categories. In multicenter interim guidance on the use of remdesivir for children with COVID-19, severe illness is defined as patients with new or increase from baseline supplemental oxygen requirement without need for new or increase in baseline noninvasive/invasive mechanical ventilation. Our patient’s disease category was assessed as severe COVID-19 based on the guidance.

While most pediatric COVID-19 patients experience mild illness, a small proportion develops severe illness associated with adverse clinical outcomes. A multinational European cohort of 582 pediatric COVID-19 cases showed that 48 cases (8%) required pediatric intensive care unit (PICU) admission and four children died. In a retrospective cohort study of 12,306 pediatric COVID-19 patients in the United States, the frequency of hospitalization was 5.5% (672 cases). Among those who were hospitalized, 17.6% required PICU admission and 4.1% required mechanical ventilation. There were ≤ 10 deaths. In data on 3,836 Italian pediatric COVID-19 cases from the national case-based surveillance system, the overall hospitalization rate and PICU admission rate were 13.3% and 3.5%, respectively. As of June 18, according to the Korea Disease Control and Prevention Agency report, there was a patient aged 10–19 years old with severe-critical status.

Data to clearly establish the risk factors for severe COVID-19 in children are limited. In a European cohort study, the significant risk factors for ICU admission were age younger than one month, male gender, pre-existing medical conditions, and the presence of lower
respiratory tract infection signs or symptoms at presentation. In a study of children with COVID-19 admitted to North American PICUs, most had underlying conditions, with obesity, chronic lung disease, and prematurity the most prevalent. Our patient had no underlying medical conditions other than obesity. Data from several studies suggested that overweight or obesity was an independent risk factor for severe COVID-19 in adults. There is insufficient evidence to definitively support isolated overweight or obesity as a risk factor for severe COVID-19 in children. However, current reports indicated that obesity was prevalent among hospitalized pediatric COVID-19 patients, particularly in a critically ill cohort.

Most children with COVID-19 will not require any specific therapy. Children with mild or moderate COVID-19 can be managed with supportive care alone. The established optimal therapy for children with severe COVID-19 is unknown. In the absence of adequate data, guidance for the treatment of pediatric COVID-19 is mostly extrapolated from recommendations for adults with COVID-19. WHO recommends against the use of remdesivir in COVID-19 patients. However, remdesivir is recommended in other guidelines for children with severe COVID-19. In the guidelines from the U.S National Institutes of Health, remdesivir is recommended for hospitalized children aged ≥ 12 years with COVID-19 who have risk factors for severe diseases and have an emergent or increasing need for supplemental oxygen. In consultation with a pediatric infectious disease specialist, remdesivir can be considered for hospitalized children of all ages with COVID-19 who have an emergent or increasing need for supplemental oxygen. Remdesivir has not been evaluated in clinical trials for children, and there have been no results from systemic evaluations of pharmacokinetics, efficacy, or toxicity in younger children, although studies are ongoing (NCT04431453). Recently, a report of the compassionate use of remdesivir in children with severe COVID-19 was published by Goldman et al. The report showed that among 77 children treated with remdesivir for severe COVID-19, most recovered and the rate of serious adverse events was low. Remdesivir may cause adverse events such as transaminase elevations, hypersensitivity reactions and bradycardia. Except the report by Goldman et al., there are only a few case reports of children with COVID-19 treated with remdesivir. Remdesivir became available for use in July 2020 in Korea. To our knowledge, no pediatric case of severe COVID-19 treated with remdesivir has been reported in Korea.

Our patient received dexamethasone for 10 days as well as remdesivir therapy. We gave significant consideration to decision-making regarding dexamethasone therapy for this patient. In current guidelines, dexamethasone is recommended for children in critical COVID-19 with evidence of hyperinflammation. However, we assessed the status of our patient who was rapidly progressing toward “critical” category. Eventually, the patient was successfully treated with remdesivir and dexamethasone.

The proportion of severe or critical disease is small in children with COVID-19. However, a small proportion of children with COVID-19 also develop progressive respiratory disease, like our patient. Further research is needed to establish the optimal treatment for children with severe or critical COVID-19.

ACKNOWLEDGMENTS

We appreciate all the staff at the isolation units and the office of Infection Control in the Pusan National University Hospital.
REFERENCES

1. World Health Organization. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/. Updated 2021. Accessed May 16, 2021.

2. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Special considerations in children. https://www.covid19treatmentguidelines.nih.gov/special-populations/children/. Updated 2021. Accesssed May 4, 2021.

3. American Academy of Pediatrics. Children and COVID-19: state-level data report. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/. Updated 2021. Accessed May 16, 2021.

4. Götzinger F, Santiago-García B, Noguera-Julían A, Lanaspa M, Lancell L, Calo Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020;4(9):653-61. PUBMED | CROSSREF

5. Parcha V, Booker KS, Kalra R, Kuranz S, Berra L, Arora G, et al. A retrospective cohort study of 12,306 pediatric COVID-19 patients in the United States. Sci Rep 2021;11(1):10231. PUBMED | CROSSREF

6. Chao JY, Derespina KR, Herold BC, Goldman DL, Aldrich M, Weingarten J, et al. Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 at a tertiary care medical center in New York City. J Pediatr 2020;223:14-19.e2. PUBMED | CROSSREF

7. Derespina KR, Kaushik S, Plichta A, Conway EE Jr, Bercow A, Choi J, et al. Clinical manifestations and outcomes of critically ill children and adolescents with coronavirus disease 2019 in New York City. J Pediatr 2020;226:55-63.e2. PUBMED | CROSSREF

8. Kim L, Whitaker M, O’Halloran A, Kambhampati A, Chai SJ, Reingold A, et al. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 - COVID-19, 14 States, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep 2020;69(32):1081-8. PUBMED | CROSSREF

9. Esposito S, Caramelli F, Principi N. What are the risk factors for admission to the pediatric intensive unit among pediatric patients with COVID-19? Ital J Pediatr 2021;47(1):103. PUBMED | CROSSREF

10. Tripathi S, Gist KM, Bjornstad EC, Kashyap R, Boman K, Chiotos K, et al. Coronavirus disease 2019-associated PICU admissions: a report from the Society of Critical Care Medicine discovery network Viral Infection and Respiratory Illness Universal Study registry. Pediatr Crit Care Med 2021;22(7):603-45. PUBMED | CROSSREF

11. Korea Disease Control and Prevention Agency. Coronavirus disease-19, Republic of Korea. http://ncov.mohw.go.kr/. Updated 2021. Accessed May 16, 2021.

12. Infectious Diseases Society of America. IDSA guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Updated 2021. Accessed May 4, 2021.

13. Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc 2021;10(1):34-48. PUBMED | CROSSREF

14. Buonsenso D, Parri N, De Rose C, Valentini P; Gemelli-pediatric COVID-19 team. Toward a clinically based classification of disease severity for pediatric patients with COVID-19. Lancet Infect Dis 2021;21(1):22. PUBMED | CROSSREF

15. Dulek DE, Fuhlbrigge RC, Tribble AC, Connelly JA, Loi MM, El Chebib H, et al. Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute coronavirus disease 2019 in pediatric patients. J Pediatric Infect Dis Soc 2020;9(6):716-37. PUBMED | CROSSREF

16. Bellino S, Punzo O, Rota MC, Del Manso M, Urdiales AM, Andrianou X, et al. COVID-19 disease severity risk factors for pediatric patients in Italy. Pediatrics 2020;146(4):e2020009399. PUBMED | CROSSREF

17. Korea Disease Control and Prevention Agency. Updates on COVID-19 in Republic of Korea (as of 18 June). http://ncov.mohw.go.kr/upload/viewer/skin/doc.html?fn=1623993396036_20210618141636.pdf&res=/ upload/viewer/result/202107/. Updated 2021. Accessed July 6, 2021.
18. Alfraij A, Bin Alamir AA, Al-Otaibi AM, Alsharrah D, Aldaiithan A, Kamel AM, et al. Characteristics and outcomes of coronavirus disease 2019 (COVID-19) in critically ill pediatric patients admitted to the intensive care unit: a multicenter retrospective cohort study. *J Infect Public Health* 2021;14(2):193-200. [PUBMED] [CROSSREF]

19. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. *JAMA Pediatr* 2020;174(9):868-73. [PUBMED] [CROSSREF]

20. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. *Ann Intern Med* 2020;173(10):773-81. [PUBMED] [CROSSREF]

21. Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. *Lancet* 2020;395(10236):1544-5. [PUBMED] [CROSSREF]

22. Rossi AP, Gottin L, Donadello K, Schweiger V, Nocini R, Taiana M, et al. Obesity as a risk factor for unfavourable outcomes in critically ill patients affected by Covid 19. *Nutr Metab Cardiovasc Dis* 2021;31(3):762-8. [PUBMED] [CROSSREF]

23. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children’s hospital in New York City, New York. *JAMA Pediatr* 2020;174(10):e202430. [PUBMED] [CROSSREF]

24. Update to living WHO guideline on drugs for covid-19. *BMJ* 2021;372(860):n860. [PUBMED]

25. Goldman DL, Aldrich ML, Hagmann SH, Bamford A, Camacho-Gonzalez A, Lapadula G, et al. Compassionate use of remdesivir in children with severe COVID-19. *Pediatrics* 2021;147(5):e2020047803. [PUBMED] [CROSSREF]

26. Gadzińska J, Kuchar E, Matysiak M, Wanke-Rytt M, Kloc M, Kubiak JZ. A 10-year-old girl with late acute lymphoblastic leukemia recurrence diagnosed with COVID-19 and treated with remdesivir. *Pediatr Hematol Oncol*. Forthcoming 2021. [PUBMED] [CROSSREF]

27. Hopwood AJ, Jordan-Villegas A, Gutierrez LD, Cowart MC, Vega-Montalvo W, Cheung WL, et al. SARS-CoV-2 pneumonia in a newborn treated with remdesivir and COVID-19 convalescent plasma. *J Pediatric Infect Dis Soc*. Forthcoming 2020.

28. Kim-Hellmuth S, Hermann M, Eilenberger J, Ley-Zaporozhan J, Fischer M, Hauck F, et al. SARS-CoV-2 triggering severe acute respiratory distress syndrome and secondary hemophagocytic lymphohistiocytosis in a 3-year-old child with down syndrome. *J Pediatric Infect Dis Soc* 2021;10(4):543-6. [PUBMED] [CROSSREF]

29. Saikia B, Tang J, Robinson S, Nichani S, Lawman KB, Katre M, et al. Neonates with SARS-CoV-2 infection and pulmonary disease safely treated with remdesivir. *Pediatr Infect Dis J* 2021;40(5):e194-6. [PUBMED] [CROSSREF]